PRAH - PRA Health Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
103.90
+2.05 (+2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close101.85
Open103.77
Bid103.94 x 1000
Ask103.75 x 1200
Day's Range103.09 - 105.39
52 Week Range82.12 - 121.98
Volume426,294
Avg. Volume605,325
Market Cap6.524B
Beta (3Y Monthly)1.52
PE Ratio (TTM)43.64
EPS (TTM)2.38
Earnings DateOct 29, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est112.55
Trade prices are not sourced from all markets
  • Should You Be Adding PRA Health Sciences (NASDAQ:PRAH) To Your Watchlist Today?
    Simply Wall St.

    Should You Be Adding PRA Health Sciences (NASDAQ:PRAH) To Your Watchlist Today?

    Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...

  • Thomson Reuters StreetEvents

    Edited Transcript of PRAH earnings conference call or presentation 1-Aug-19 1:00pm GMT

    Q2 2019 PRA Health Sciences Inc Earnings Call

  • Raleigh company's largest investor to sell all of its shares — $600M-plus
    American City Business Journals

    Raleigh company's largest investor to sell all of its shares — $600M-plus

    A Raleigh-based clinical research organization plans a stock buyback worth half a billion dollars as its largest institutional shareholder plans to sell its stake.

  • GlobeNewswire

    PRA Health Sciences, Inc. Announces Pricing of Secondary Offering and Concurrent Share Repurchase

    PRA Health Sciences, Inc. (the “Company”) (PRAH) today announced the pricing of the previously announced secondary offering of shares of its common stock.  KKR PRA Investors L.P. (the “Selling Stockholder”), has agreed to sell an aggregate of 6,666,684 shares of the Company’s common stock in an underwritten public offering at a price of $97.50 per share. In addition, the Company announced that, subject to the completion of the offering, it intends to repurchase from the underwriter, out of 6,666,684 shares of common stock, a number of shares having an aggregate purchase price of $300 million at a price per share equal to the price at which the underwriter will purchase the shares from the Selling Stockholder. The Company intends to fund the repurchase of common stock from the Selling Stockholder with the proceeds of a $300 million incremental term loan under its existing credit facilities.

  • GlobeNewswire

    PRA Health Sciences, Inc. Announces $500 Million Share Repurchase Program

    Under the program, the Company is authorized to repurchase shares of its common stock through open market purchases, privately-negotiated transactions, secondary offerings, block trades or otherwise in accordance with all applicable securities laws and regulations, including through trading plans complying with the rules and regulations of the Securities and Exchange Commission (the “SEC”). In addition, the Company announced that, subject to the completion of the announced underwritten secondary offering of the Company’s common stock by KKR PRA Investors L.P. (the “Selling Stockholder”), it intends to repurchase from the underwriter in such offering, out of the 6,666,684 shares of common stock, a number of shares having an aggregate purchase price of $300 million at a price per share equal to the price at which the underwriter will purchase the shares from the Selling Stockholder.

  • GlobeNewswire

    PRA Health Sciences, Inc. Announces Secondary Offering and Concurrent Share Repurchase

    PRA Health Sciences, Inc. (the “Company”) (PRAH) today announced that KKR PRA Investors L.P. (the “Selling Stockholder”), intends to offer for sale in an underwritten secondary offering 6,666,684 shares of common stock of the Company pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission. No shares are being sold by the Company. The last reported sale price of the Company’s common stock on September 3, 2019 was $97.59 per share.

  • Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign
    Investor's Business Daily

    Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish Sign

    Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.

  • PRA Health Sciences (NASDAQ:PRAH) Has A Pretty Healthy Balance Sheet
    Simply Wall St.

    PRA Health Sciences (NASDAQ:PRAH) Has A Pretty Healthy Balance Sheet

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    PRA Health Sciences Announces Strategic Alliance between Symphony Health and Close-Up International

    PRA Health Sciences (PRAH) announced today that Symphony Health, the company’s data solutions division, has expanded its global data services by entering into a strategic partnership with Close-Up International, a leading Latin American-based provider of medical prescription and sales audits. “The agreement with Close-Up represents a significant milestone in Symphony Health’s commitment to expanding our services internationally,” said Doug Fulling, President of Symphony Health. “The presence across up to a dozen geographies adds a critical component to Symphony’s offerings that will build and strengthen relationships for both organizations in the United States and Latin America.

  • Raleigh CRO looks to leverage resources to expand Asian markets
    American City Business Journals

    Raleigh CRO looks to leverage resources to expand Asian markets

    A Triangle-based contract research organization says Asian-Pacific markets present a massive opportunity for expansion, potentially adding to its already double-digit growth.

  • PRA Health (PRAH) Q2 Earnings Beat, EPS Guidance Narrowed
    Zacks

    PRA Health (PRAH) Q2 Earnings Beat, EPS Guidance Narrowed

    PRA Health (PRAH) slashes 2019 revenue guidance; direct costs surge in second quarter.

  • PRA Health Sciences, Inc. (PRAH) Q2 2019 Earnings Call Transcript
    Motley Fool

    PRA Health Sciences, Inc. (PRAH) Q2 2019 Earnings Call Transcript

    PRAH earnings call for the period ending June 30, 2019.

  • PRA Health Sciences (PRAH) Beats Q2 Earnings Estimates
    Zacks

    PRA Health Sciences (PRAH) Beats Q2 Earnings Estimates

    PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 1.67% and -0.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    PRA Health Sciences, Inc. Reports Second Quarter 2019 Results and Updates Full Year 2019 Guidance

    Net new business of $670.7 million; Net book-to-bill of 1.24$763.3 million of total revenue; representing 5.6% growth at actual foreign exchange rates and 6.8% growth on a.

  • Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More
    Zacks

    Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More

    Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.

  • What PRA Health Sciences, Inc.'s (NASDAQ:PRAH) ROE Can Tell Us
    Simply Wall St.

    What PRA Health Sciences, Inc.'s (NASDAQ:PRAH) ROE Can Tell Us

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • PRA Health Sciences (PRAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    PRA Health Sciences (PRAH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    CORRECTING and REPLACING -- PRA Health Sciences to Report Second Quarter 2019 Earnings

    In a release issued under the same headline on July 9, 2019 by PRA Health Sciences, Inc. (PRAH), please note that in the second paragraph of the release, the conference call ID and replay ID should read "6295812" and not "1876878" as previously stated. PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2019 results after the market closes on Wednesday, July 31, 2019. The Company will also host a conference call on Thursday, August 1, 2019 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

  • GlobeNewswire

    PRA Health Sciences to Report Second Quarter 2019 Earnings

    RALEIGH, N.C., July 09, 2019 -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2019 results after the market closes on Wednesday, July 31, 2019. The.

  • Is PRA Health Sciences's (NASDAQ:PRAH) 142% Share Price Increase Well Justified?
    Simply Wall St.

    Is PRA Health Sciences's (NASDAQ:PRAH) 142% Share Price Increase Well Justified?

    It hasn't been the best quarter for PRA Health Sciences, Inc. (NASDAQ:PRAH) shareholders, since the share price has...

  • Here’s What Hedge Funds Think About PRA Health Sciences Inc (PRAH)
    Insider Monkey

    Here’s What Hedge Funds Think About PRA Health Sciences Inc (PRAH)

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

  • Here's Why You Should Hold on to PRA Health (PRAH) Stock Now
    Zacks

    Here's Why You Should Hold on to PRA Health (PRAH) Stock Now

    PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.

  • Markit

    See what the IHS Markit Score report has to say about PRA Health Sciences Inc.

    PRA Health Sciences Inc NASDAQ/NGS:PRAHView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for PRAH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PRAH. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PRAH totaled $150 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PRA Health Sciences (PRAH) Down 5.1% Since Last Earnings Report: Can It Rebound?
    Zacks

    PRA Health Sciences (PRAH) Down 5.1% Since Last Earnings Report: Can It Rebound?

    PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    PRA Health Sciences Earns Recognition, Industry Awards

    PRA Health Sciences, Inc. is pleased to announce it has received an array of awards and recognition during the first months of 2019. This is the seventh consecutive year that the company has won this prestigious industry award. Clinical Researcher of the Year – The Americas is a real-world competition that recognizes the talent and passion of industry and academic researchers and is considered a key barometer of quality standards in the clinical research organization (CRO) industry.